Laboratories, MRI & Dialysis Deals Dropped in 2016

by | Mar 29, 2017 1:57 pm | Laboratories, MRI & Dialysis | 0 comments

Deal volume settled down in 2016, following a very busy 2015 in the Laboratories, MRI & Dialysis sector. The 41 deals recorded represent a 21% decline compared with the 52 announced in 2015. Laboratories have had to adapt as hospitals and health systems have merged or closed in recent years. Some labs have evolved to offer coordinated diagnostics: offering tests that give on-the-spot diagnoses, handling bills and lab data from several sources and providers as an aid to accountable care organizations, and focusing on the patient experience to ensure repeat business. At the same time, deal value surged in 2016, up 166% year-over-year to $11.6 billion. Two multi-billion-dollar deals... Read More »

Bracket Changes Hands Again

by | Mar 28, 2017 7:55 pm | CRO, eHealth, Other Services, Private Equity | 0 comments

It may not be news to digital health sector watchers that Bracket, a privately held clinical trial technology provider, was sold again. On March 28, 2017, San Francisco private equity firm Genstar Capital purchased the company for an undisclosed price. Bracket, a Pennsylvania-based clinical trial technology, has changed hands several times over the years. Bracket serves biotechnology and pharmaceutical companies, as well as clinial research organizations. It leverages Bracket eCOA™, a platform for electronic clinical outcomes assessments that collects information from patients (ePRO), clinicians (eClinRO) and other observers (eObsRO). The company started off as a division of United... Read More »

Where Have All the Big Pharma Deals Gone?

by | Mar 28, 2017 7:43 pm | Biotechnology, Pharmaceuticals | 0 comments

The Pharmaceutical sector has experienced a dearth of big deals so far this year. In Q1:16, 40 transactions with pharmaceutical targets were announced, for a total of $46.2 billion. In the first quarter of 2017 (through March 28), only 24 deals (-40%) for pharmaceutical targets have been announced, with a combined total of $10.1 billion (-78%). One factor behind the drop in deals is obvious. The sector came under legislative and consumer scrutiny during the presidential election in 2016, as candidates Hillary Clinton and Donald Trump each decried high prices charged by drug manufacturers, and each vowed to do something about it once elected. President Trump repeated his campaign promise to... Read More »

Kohlberg and Co. Expands its Alita Care Platform

by | Mar 28, 2017 3:40 pm | Behavioral Health Care, Private Equity | 0 comments

Private equity companies are driving most behavioral health activity in 2017, as they continue to trade practices and build up regional platforms. Through March 28, 2017, 12 behavioral health care deals are on the books. Nearly 60% of these deals were announced by financial buyers, six of which were PE- backed behavioral health companies. One was a private equity firm and one a blank-check investment firm. In April 2016, American Capital Ltd. (NASDAQ: ACAS) announced the sale of its portfolio company, The Meadows of Wickenburg, Inc., to Kohlberg & Company LLC, a New York-based private equity firm, for $180 million. Located in Arizona, The Meadows provides addiction and... Read More »